Defence Therapeutics (XCNQ:DTC) Debt-to-Equity : -0.66 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Debt-to-Equity?

Defence Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.49 Mil. Defence Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.02 Mil. Defence Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-2.30 Mil. Defence Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.66.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Defence Therapeutics's Debt-to-Equity or its related term are showing as below:

XCNQ:DTC' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.71 Med: -0.74 Max: 1.23
Current: -0.66

During the past 3 years, the highest Debt-to-Equity Ratio of Defence Therapeutics was 1.23. The lowest was -3.71. And the median was -0.74.

XCNQ:DTC's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:DTC: -0.66

Defence Therapeutics Debt-to-Equity Historical Data

The historical data trend for Defence Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Debt-to-Equity Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Debt-to-Equity

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										-	-0.82	1.23	-3.71	-0.66

Competitive Comparison of Defence Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Defence Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Defence Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Debt-to-Equity falls into.

Defence Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Defence Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.388
	=	0.00

Defence Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.492	+	0.023)	/	-2.295
	=	-0.66

Defence Therapeutics (XCNQ:DTC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Defence Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.